Form 8-K - Current report:
SEC Accession No. 0001558370-25-007259
Filing Date
2025-05-12
Accepted
2025-05-12 08:00:19
Documents
15
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avbp-20250512x8k.htm   iXBRL 8-K 39842
2 EX-99.1 avbp-20250512xex99d1.htm EX-99.1 154368
3 GRAPHIC avbp-20250512xex99d1001.jpg GRAPHIC 5560
  Complete submission text file 0001558370-25-007259.txt   339740

Data Files

Seq Description Document Type Size
4 EX-101.SCH avbp-20250512.xsd EX-101.SCH 3411
5 EX-101.LAB avbp-20250512_lab.xml EX-101.LAB 16581
6 EX-101.PRE avbp-20250512_pre.xml EX-101.PRE 10714
17 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20250512x8k_htm.xml XML 5051
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 25932660
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)